Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies

LIEVE VAN HOOVELS, STEFANIE VAN DEN BREMT, TOON SCHIEMSKY, MATHIEU CAUCHIE, BERT VANDER CRUYSSEN, XAVIER BOSSUYT, KRIS VAN DER STEEN and MURIEL STUBBE
The Journal of Rheumatology February 2019, 46 (2) 215-216; DOI: https://doi.org/10.3899/jrheum.180432
LIEVE VAN HOOVELS
Department of Laboratory Medicine, Onze-Lieve-Vrouw Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for LIEVE VAN HOOVELS
  • For correspondence: lieve.van.hoovels@olvz-aalst.be
STEFANIE VAN DEN BREMT
Department of Laboratory Medicine, Onze-Lieve-Vrouw Hospital;
Roles: Medical Laboratory Technician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for STEFANIE VAN DEN BREMT
TOON SCHIEMSKY
Department of Laboratory Medicine, Onze-Lieve-Vrouw Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for TOON SCHIEMSKY
MATHIEU CAUCHIE
Department of Laboratory Medicine, Onze-Lieve-Vrouw Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for MATHIEU CAUCHIE
BERT VANDER CRUYSSEN
Department of Rheumatology, Onze-Lieve-Vrouw Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XAVIER BOSSUYT
Department of Laboratory Medicine, University Hospital Leuven, Leuven;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KRIS VAN DER STEEN
Department of Clinical Pathology, Onze-Lieve-Vrouw Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MURIEL STUBBE
Department of Rheumatology, Onze-Lieve-Vrouw Hospital, Aalst, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We read with interest the article by Kopylov, et al, who reported small bowel inflammation consistent with Crohn disease (CD) in 42.2% of patients with spondyloarthropathy (SpA) by video capsule endoscopy1.

The link between bowel and joint in SpA has been established for several decades. Already in the 1980s, it was demonstrated that up to 50% of all patients with SpA have microscopic bowel inflammation, without associated gastrointestinal (GI) symptoms2. Calprotectin is a heterodimeric complex of two S100 calcium-binding proteins, myeloid-related protein (MRP)-8 (S100A8) and MRP-14 (S100A9), expressed in granulocytes and monocytes3. Fecal calprotectin (FC) is a sensitive and specific biomarker of intestinal inflammation, and quantification of FC is useful for diagnosis and followup of inflammatory bowel diseases (IBD)4,5. Also in patients with SpA, FC has been shown to reveal GI inflammation before clinical onset6, which was confirmed by Kopylov and colleagues.

In daily practice, the diagnosis of SpA based on the Assessment of Spondyloarthritis international Society (ASAS) criteria is hampered by a relative low sensitivity of 79.5%7. We wondered whether the analysis of FC could add value to the diagnostic process of SpA.

We therefore quantified FC in 99 adult patients who for the first time presented with a clinical suspicion of SpA. Final SpA diagnosis (n = 52) was based on expert opinion. Patients were asked to discontinue intake of nonsteroidal antiinflammatory drugs 2 weeks before sample collection, and patients previously diagnosed with IBD were excluded. Three commercially available FC assays (Quantum Blue Calprotectin, Bühlmann; QUANTA Lite Calprotectin Extended Range, Inova Diagnostics; LIAISON Calprotectin, DiaSorin) were performed on each sample.

A summary of the diagnostic performance of the different FC assays in SpA diagnosis is shown in Table 1. In concordance with the findings of Kopylov, et al, FC levels were significantly higher in the SpA group versus the non-SpA group (Supplementary Figure 1, available from the authors on request). A receiver-operating curve analysis was performed to reveal the diagnostic performance for the different FC assays for SpA. The area under the curve did not differ significantly among assays, but there was a significant difference in sensitivity and specificity for SpA when the manufacturer’s cutoffs were applied. At a cutoff of 98% specificity for SpA, sensitivities of 13%, 21%, and 8% were obtained for, respectively, the FC assays Quantum Blue Calprotectin, LIAISON Calprotectin, and QUANTA Lite Calprotectin Extended Range. Only for the FC LIAISON Calprotectin assay was a significant OR between the SpA and non-SpA patient group revealed, increasing the probability for SpA 6.8-fold for a patient with a positive FC test with the LIAISON Calprotectin assay (Table 1). Likelihood ratios [LR; i.e., the likelihood (%) for patients with SpA divided by the likelihood (%) for controls] were calculated for different FC test result intervals. The probability of SpA increased with FC, and LR of 0.5, 2.0, and 9.9 for FC of ≤ 20, 21–62, 63–200 µg/g were obtained for the LIAISON Calprotectin FC assay. These results show that on the one hand, low FC cannot exclude the diagnosis of SpA (LR of 0.5), and on the other hand, that high FC cannot be used to diagnose SpA (LR of 9.9). Nevertheless, as shown in Table 2, FC improved diagnostic sensitivity if combined with radiology and HLA-B27 analysis in the diagnostic process of patients with suspicion of SpA. For 67 of 99 patients, imaging [radiograph and/or magnetic resonance imaging (MRI)] and HLA-B27 analysis were available and both examinations resulted in an overall sensitivity and specificity for SpA of 67% and 84%, respectively. Adding FC improved the diagnostic sensitivity to 74% (Table 2), without reducing specificity. The corresponding LR was 4.6 (indicating a moderate difference in pretest to posttest probability).

View this table:
  • View inline
  • View popup
Table 1.

Diagnostic performance of different fecal calprotectin assays to support the diagnosis of SpA.

View this table:
  • View inline
  • View popup
Table 2.

Performance of different tests to support the diagnosis of SpA.

Further, FC results could also be used to guide patient management in SpA8. Bowel inflammation seems to be an important prognostic factor in SpA; it was shown to be associated with more extensive bone marrow edema of the sacroiliac joints, a higher risk of progression to ankylosing spondylitis, and a higher risk of developing CD9. Even in the absence of clinical symptoms, endoscopic investigation of patients with elevated FC is advocated. If endoscopy and histologic analysis reveal evidence of active CD, therapeutic management of patients with SpA could be changed, by choosing a treatment option that is effective for both CD and SpA (e.g., adalimumab, infliximab, ustekunimab)10. In the study by Kopylov, et al, the finding of CD led to a change in patient management in 65.2% of cases1. The guidance of SpA management based on FC results is promising and merits further investigation.

FC analysis in combination with imaging and HLA-B27 analysis improves the diagnostic sensitivity in SpA.

Acknowledgment

We thank DiaSorin and Inova for the donation of the assays. We are very thankful to the laboratory technicians for their efforts.

REFERENCES

  1. 1.↵
    1. Kopylov U,
    2. Starr M,
    3. Watts C,
    4. Dionne S,
    5. Girardin M,
    6. Seidman EG
    . Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study. J Rheumatol 2018;45:498–505.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cuvelier C,
    2. Barbatis C,
    3. Mielants H,
    4. De Vos M,
    5. Roels H,
    6. Veys E
    .Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987;28:394–401.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Vogl T,
    2. Tenbrock K,
    3. Ludwig S,
    4. Leukert N,
    5. Ehrhardt C,
    6. van Zoelen MA,
    7. et al.
    Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Menees SB,
    2. Powell C,
    3. Kurlander J,
    4. Goel A,
    5. Chey WD
    . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lin JF,
    2. Chen JM,
    3. Zuo JH,
    4. Yu A,
    5. Xiao ZJ,
    6. Deng FH,
    7. et al.
    Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20:1407–15.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Cypers H,
    2. Varkas G,
    3. Beeckman S,
    4. Debusschere K,
    5. Vogl T,
    6. Roth J,
    7. et al.
    Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 2015;75:1357–62.
    OpenUrl
  7. 7.↵
    1. Rudwaleit M,
    2. van der Heijde D,
    3. Landewé R,
    4. Akkoc N,
    5. Brandt J,
    6. Chou CT,
    7. et al.
    The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. De Wilde K,
    2. Debusschere K,
    3. Beeckman S,
    4. Jacques P,
    5. Elewaut D
    . Integrating the pathogenesis of spondyloarthritis: Gut and joint united? Curr Opin Rheumatol 2015;27:189–96.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Van Praet L,
    2. Jans L,
    3. Carron P,
    4. Jacques P,
    5. Glorieus E,
    6. Colman R,
    7. et al.
    Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: Results from the giant cohort. Ann Rheum Dis 2014;73:1186–9.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Braun J,
    2. Baraliakos X,
    3. Listing J,
    4. Davis J,
    5. van der Heijde D,
    6. Haibel H,
    7. et al.
    Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639–47.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 2
1 Feb 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies
LIEVE VAN HOOVELS, STEFANIE VAN DEN BREMT, TOON SCHIEMSKY, MATHIEU CAUCHIE, BERT VANDER CRUYSSEN, XAVIER BOSSUYT, KRIS VAN DER STEEN, MURIEL STUBBE
The Journal of Rheumatology Feb 2019, 46 (2) 215-216; DOI: 10.3899/jrheum.180432

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Added Value of Fecal Calprotectin to Support the Diagnosis of Spondyloarthropathies
LIEVE VAN HOOVELS, STEFANIE VAN DEN BREMT, TOON SCHIEMSKY, MATHIEU CAUCHIE, BERT VANDER CRUYSSEN, XAVIER BOSSUYT, KRIS VAN DER STEEN, MURIEL STUBBE
The Journal of Rheumatology Feb 2019, 46 (2) 215-216; DOI: 10.3899/jrheum.180432
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • To the Editor:
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire